Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959327 | 1.00 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL13606646 | 1.00 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL21275009 | 0.86 | CHRM2 (0.36) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL15786676 | 0.86 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL14239075 | 0.86 | CHRM2 (0.36) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL21274752 | 0.85 | SPHK1 (0.35) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL21244705 | 0.85 | SPHK1 (0.35) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL22443436 | 0.85 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL3659522 | 0.85 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL21441794 | 0.84 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-01-09 | — | — | US | disclosed |
| CN-113683614-B | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4356969-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20200123167-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2020-04-23 | — | — | US | disclosed |
| CN-109863151-A | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-109843856-A | KRAS G12C inhibitor | 米拉蒂治疗股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2018042303-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057501-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057501-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885CHRM2 4880/4885CHRM1 4874/4885 |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL1 | NR1H2 839/4885CHRM2 1617/4885CHRM1 621/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | NR1H2 1265/4885CHRM2 353/4885CHRM1 145/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885CHRM2 4880/4885CHRM1 4874/4885 |
| US-20180057501-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL5 | NR1H2 816/4885CHRM2 1650/4885CHRM1 1032/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885CHRM2 4880/4885CHRM1 4874/4885 |
| US-20200123167-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL5 | NR1H2 816/4885CHRM2 1650/4885CHRM1 1032/4885 |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | ZC3HAV1, ZC3HAV1L, CUL5 | NR1H2 816/4885CHRM2 1650/4885CHRM1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.